Johnson & Johnson Proposes $5.5 Billion Settlement for Talc-Related Ovarian Cancer Lawsuits

Johnson & Johnson (NYSE: JNJ) on Monday announced a proposed agreement to pay $5.5 billion to resolve the vast majority of its remaining U.S. lawsuits alleging its talc-based products caused ovarian cancer. The settlement is contingent upon securing agreement from at least 95% of the claimants.

Details of the Agreement

The proposed deal aims to conclude more than 15 years of litigation by settling approximately 76,000 outstanding claims currently consolidated in federal multidistrict litigation (MDL) and various state courts. Johnson & Johnson stated that this path provides an efficient resolution for all parties.

Under the terms outlined by the company, the payment structure would be staggered:

• The first payment, not to exceed $3 billion, would be made in 2027.
• No additional payments would be due before 2028.

Legal and Corporate Context

Ad

This settlement offer follows a recent ruling in the federal MDL court that questioned the ability of plaintiffs to scientifically prove that the company's talc products were the specific cause of any individual's ovarian cancer. According to J&J, plaintiffs had withdrawn their causation experts in two key bellwether cases just before the court ordered them to justify why the remaining claims should not be dismissed.

While proposing the settlement to eliminate the costs and uncertainty of continued litigation, Johnson & Johnson reiterated its long-held position that its talc products are safe. The company maintains that decades of scientific research support that its cosmetic talc does not contain asbestos or cause cancer.

Market and Product Background

The ongoing legal battle has been a significant overhang for the company for years. In 2023, Johnson & Johnson discontinued the sale of its talc-based Johnson's Baby Powder globally, switching to a cornstarch-based formula.

Following the spinoff of its consumer health business into the publicly traded company Kenvue, Johnson & Johnson retained all liabilities related to the talc litigation. This proposed settlement represents a significant step toward resolving one of the largest and most complex mass tort litigations in U.S. history, potentially removing a major source of uncertainty for investors.